Darrin M Beaupre MD, PhD

Senior Vice President, Head of Early Oncology Development and Clinical Research
Media Name: darrin_beaupre_050418_300x170.jpg

I joined Pfizer in 2017 and am a Senior Vice President in the Pfizer Early Oncology Research and Development Group. I focus on clinical development of early oncology assets. Prior to joining Pfizer, I was the Head of Early Development and Immunotherapy at Pharmacyclics (an Abbvie company). I was the clinical lead for the first Ibrutinib FDA approval in mantle cell lymphoma that was associated with a New England Journal of Medicine publication. I also led the Ibrutinib clinical team responsible for the first approved therapy in marginal zone lymphoma. As a faculty member of the Moffitt Cancer Center, I was the recipient of a Hollis Brownstein Research Grant and was recognized as a “Scientist to Watch” by the Leukemia Research Foundation. I also received multiple Clinical Scholars in Oncology Awards from the National Cancer Institute.


My group (Early Oncology Development and Clinical Research-EODCR) is responsible for the early clinical development portfolio here at Pfizer. It consists of leaders from clinical development, clinical pharmacology, translational oncology, and other supportive areas. Our responsibility is to work closely with our discovery research and late development colleagues to transition our molecules from discovery to pivotal trial testing. In early development our responsibilities include performing first in human clinical trials with the goal of determining the safety profile and early efficacy signals of our novel molecules. Along with this, understanding the appropriate dose and schedule, indications to pursue, and combination partners to test are key deliverables from our group. In addition, a large focus on translational medicine is pursued in EODCR. Understanding pharmacokinetics, pharmacodynamics, resistance mechanisms, and subject selection strategies associated with our molecules is of paramount importance. The high functioning scientists and physicians as well as supporting staff that make up this group allow us to achieve these goals on a daily basis.


  1. Targeting BTK with Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma A. Noy, S. de Vos, C. Thieblemont, P. Martin, C.R. Flowers, F. Morschhauser, G.P. Collins, S. Ma, M. Coleman, S. Peles, S. Smith, J.C. Barrientos, A. Smith, B. Munneke, I. Dimery, D.M. Beaupre, R. Chen, manuscript accepted in Blood, January 2017.
  2. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma H.P. Kuo, S. A. Ezell, S. Hsieh, K.J. Schweighofer, L.W.K. Cheung, S.Wu, M. Apatira, M. Sirisawad, K. Eckert, Y. Liang, J. Hsu, C. Chen, D. Beaupre, and B. Y. Chang, manuscript accepted in American Journal of Cancer Research, October 2016.
  3. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors D.S. Hong, P. Rosen, C. Lockhart, S. Fu, F. Janku, R. Kurzrock, R. Khan, B. Amore, I. Caudillo, H. Deng, Y.C. Hwang, R. Loberg, G. Ngarmchamnanrith, D.M. Beaupre, P. Lee, manuscript accepted in Oncotarget, June 2015.
  4. Long-term Follow-up of MCL Patients Treated with Single-agent Ibrutinib: Updated Safety and Efficacy Results M.L. Wang, K.A. Blum, P. Martin, A. Goy, R. Auer, B.S. Kahl, W. Jurczak, R.H. Advani, J.E. Romaguera, M. Williams, J.C. Barrientos, E. Chmielowska, J. Radford, S. Stilgenbauer, M. Dreyling, W.W. Jedrzejczak, P. Johnson, S.E. Spurgeon, L. Zhang, L. Baher, M. Cheng, D. Lee, D.M. Beaupre, S. Rule, manuscript accepted in Blood, April 2015.
  5. Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma W.H. Wilson, R.M. Young, R. Schmitz, Y. Yang, S. Pittaluga, G. Wright, C.J. Lih, P. M. Williams, A. L. Shaffer, J. Gerecitano, S. De Vos, A. Goy, V. P. Kenkre, P. M. Barr, K. Blum, A. Shustov, R. Advani, N. H. Fowler, J. M. Vose, R. Elstrom, T. M. Habermann, J. C. Barrientos, J. McGreivy, B. Chang, F. Clow, D. Moussa, D. M. Beaupre, L. M. Staudt, manuscript accepted in Nature Medicine, April 2015.


University of Lowell, Biological Sciences, B.S., 1990
University of Lowell, Biological Sciences, M.S., 1990
University of Texas M.D., Anderson Cancer Center, Cancer Biology, Ph.D., 1997
University of Texas, Medicine, M.D., 1997


Recipient of the Hollis Brownstein Research Grant
Recognized as a “Scientist to Watch” by the Leukemia Research Foundation
Received multiple Clinical Scholars in Oncology Awards from the National Cancer Institute

I joined Pfizer due to the depth and promise of the Pfizer oncology early development portfolio. Pfizer is committed to leadership and excellence in the oncology space, which make innovative science and medicine a reality in our day to day activities.